메뉴 건너뛰기




Volumn 24, Issue 6, 2013, Pages 1587-1593

A phase II multicenter trial of hyperCVAD MTX/Ara-C and rituximab in patients with previously untreated mantle cell lymphoma; SWOG 0213

Author keywords

Dose intensive; Mantle cell; Rituximab

Indexed keywords

BUSULFAN; CYCLOPHOSPHAMIDE; CYTARABINE; DOXORUBICIN; ETOPOSIDE; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

EID: 84878457954     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdt070     Document Type: Article
Times cited : (107)

References (20)
  • 1
    • 0036499084 scopus 로고    scopus 로고
    • Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival
    • Howard OM, Gribben JG, Neuberg DS et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288-1294.
    • (2002) J Clin Oncol , vol.20 , pp. 1288-1294
    • Howard, O.M.1    Gribben, J.G.2    Neuberg, D.S.3
  • 2
    • 20144376591 scopus 로고    scopus 로고
    • Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG)
    • Lenz G, Dreyling M, Hoster E et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005; 23: 1984-1992.
    • (2005) J Clin Oncol , vol.23 , pp. 1984-1992
    • Lenz, G.1    Dreyling, M.2    Hoster, E.3
  • 3
    • 77954334194 scopus 로고    scopus 로고
    • Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma
    • Romaguera JE, Fayad LE, Feng L et al. Ten-year follow-up after intense chemoimmunotherapy with rituximab-hyperCVAD alternating with rituximab-high dose methotrexate/cytarabine (R-MA) and without stem cell transplantation in patients with untreated aggressive mantle cell lymphoma. Br J Haematol 2010; 150: 200-208.
    • (2010) Br J Haematol , vol.150 , pp. 200-208
    • Romaguera, J.E.1    Fayad, L.E.2    Feng, L.3
  • 4
    • 0033970534 scopus 로고    scopus 로고
    • The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997
    • Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the haematopoietic and lymphoid tissues: report of the Clinical Advisory Committee Meeting, Airlie House, Virginia, November 1997. Histopathology 2000; 36: 69-86.
    • (2000) Histopathology , vol.36 , pp. 69-86
    • Harris, N.L.1    Jaffe, E.S.2    Diebold, J.3
  • 5
    • 27244452464 scopus 로고    scopus 로고
    • High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine
    • Romaguera JE, Fayad L, Rodriguez MA et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013-7023.
    • (2005) J Clin Oncol , vol.23 , pp. 7013-7023
    • Romaguera, J.E.1    Fayad, L.2    Rodriguez, M.A.3
  • 6
    • 33845382806 scopus 로고
    • Nonparametric estimation from incomplete observations
    • Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
    • (1958) J Am Stat Assoc , vol.53 , pp. 457-481
    • Kaplan, E.1    Meier, P.2
  • 7
    • 0000336139 scopus 로고
    • Regression models and life tables
    • Cox D. Regression models and life tables. J R Stat Assoc 1972; 34: 187-220.
    • (1972) J R Stat Assoc , vol.34 , pp. 187-220
    • Cox, D.1
  • 8
    • 0027444652 scopus 로고
    • The International Non-Hodgkin's Lymphoma Prognostic Factors Project
    • A predictive model for aggressive non-Hodgkin's lymphoma
    • A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. N Engl J Med 1993; 329: 987-994.
    • (1993) N Engl J Med , vol.329 , pp. 987-994
  • 9
    • 38349104577 scopus 로고    scopus 로고
    • A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma
    • Hoster E, Dreyling M, Klapper W et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 2008; 111: 558-565.
    • (2008) Blood , vol.111 , pp. 558-565
    • Hoster, E.1    Dreyling, M.2    Klapper, W.3
  • 10
    • 84872054301 scopus 로고    scopus 로고
    • CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte
    • Delarue R, Haioun C, Ribrag V et al. CHOP and DHAP plus rituximab followed by autologous stem cell transplantation in mantle cell lymphoma: a phase 2 study from the Groupe d'Etude des Lymphomes de l'Adulte. Blood 2013; 121: 48-53.
    • (2013) Blood , vol.121 , pp. 48-53
    • Delarue, R.1    Haioun, C.2    Ribrag, V.3
  • 11
    • 84863822702 scopus 로고    scopus 로고
    • Nordic MCL2 trial update: six-year followup after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur
    • Geisler CH, Kolstad A, Laurell A et al. Nordic MCL2 trial update: six-year followup after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem-cell support: still very long survival but late relapses do occur. Br J Haematol 2012; 158: 355-362.
    • (2012) Br J Haematol , vol.158 , pp. 355-362
    • Geisler, C.H.1    Kolstad, A.2    Laurell, A.3
  • 12
    • 53449089095 scopus 로고    scopus 로고
    • Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group
    • Geisler CH, Kolstad A, Laurell A et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008; 112: 2687-2693.
    • (2008) Blood , vol.112 , pp. 2687-2693
    • Geisler, C.H.1    Kolstad, A.2    Laurell, A.3
  • 13
    • 84855796484 scopus 로고    scopus 로고
    • Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi
    • Merli F, Luminari S, Ilariucci F et al. Rituximab plus HyperCVAD alternating with high dose cytarabine and methotrexate for the initial treatment of patients with mantle cell lymphoma, a multicentre trial from Gruppo Italiano Studio Linfomi. Br J Haematol 2012; 156: 346-353.
    • (2012) Br J Haematol , vol.156 , pp. 346-353
    • Merli, F.1    Luminari, S.2    Ilariucci, F.3
  • 14
    • 84857748460 scopus 로고    scopus 로고
    • Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database
    • Lacasce AS, Vandergrift JL, Rodriguez MA et al. Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood 2012; 119(9): 2093-2099.
    • (2012) Blood , vol.119 , Issue.9 , pp. 2093-2099
    • Lacasce, A.S.1    Vandergrift, J.L.2    Rodriguez, M.A.3
  • 15
    • 85014234123 scopus 로고    scopus 로고
    • Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study
    • Lefrere F, Delmer A, Suzan F et al. Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study. Leukemia 2002; 16: 587-593.
    • (2002) Leukemia , vol.16 , pp. 587-593
    • Lefrere, F.1    Delmer, A.2    Suzan, F.3
  • 16
    • 78951495411 scopus 로고    scopus 로고
    • Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net)
    • Hermine O, Hoster E, Walewski J et al. Alternating courses of 3x CHOP and 3x DHAP plus rituximab followed by a high dose ARA-C containing myeloablative regimen and autologous stem cell transplantation (ASCT) is superior to 6 courses CHOP plus rituximab followed by myeloablative radiochemotherapy and ASCT in mantle cell lymphoma: results of the MCL younger trial of the European Mantle Cell Lymphoma Network (MCL net). ASH Annu Meeting Abstr 2010; 116: 110.
    • (2010) ASH Annu Meeting Abstr , vol.116 , pp. 110
    • Hermine, O.1    Hoster, E.2    Walewski, J.3
  • 17
    • 84864715966 scopus 로고    scopus 로고
    • Treatment of older patients with mantle-cell lymphoma
    • Kluin-Nelemans HC, Hoster E, Hermine O et al. Treatment of older patients with mantle-cell lymphoma. N Engl J Med 2012; 367: 520-531.
    • (2012) N Engl J Med , vol.367 , pp. 520-531
    • Kluin-Nelemans, H.C.1    Hoster, E.2    Hermine, O.3
  • 18
    • 79959722615 scopus 로고    scopus 로고
    • An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma
    • Witzig TE, Vose JM, Zinzani PL et al. An international phase II trial of singleagent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 2011; 22: 1622-1627.
    • (2011) Ann Oncol , vol.22 , pp. 1622-1627
    • Witzig, T.E.1    Vose, J.M.2    Zinzani, P.L.3
  • 19
    • 79953182631 scopus 로고    scopus 로고
    • Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study
    • Ansell SM, Tang H, Kurtin PJ et al. Temsirolimus and rituximab in patients with relapsed or refractory mantle cell lymphoma: a phase 2 study. Lancet Oncol 2011; 12: 361-368.
    • (2011) Lancet Oncol , vol.12 , pp. 361-368
    • Ansell, S.M.1    Tang, H.2    Kurtin, P.J.3
  • 20
    • 84860430028 scopus 로고    scopus 로고
    • The Bruton's tyrosine kinase inhibitor PCI- 32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial
    • Wang L, Martin P, Blum KA et al. The Bruton's tyrosine kinase inhibitor PCI- 32765 is highly active as single-agent therapy in previously-treated mantle cell lymphoma (MCL): preliminary results of a phase II trial. ASH Annu Meeting Abstr 2011; 118: 442-.
    • (2011) ASH Annu Meeting Abstr , vol.118 , pp. 442
    • Wang, L.1    Martin, P.2    Blum, K.A.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.